Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13280353 | 0.85 | TDP1 (0.47) | TDP1ABL1MEN1KMT2AKDM4E | |
| SCHEMBL2043408 | 0.84 | MEN1 (0.50) | TDP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL12000739 | 0.84 | TDP1 (0.49) | TDP1ABL1MEN1KMT2AKDM4E | |
| SCHEMBL2310798 | 0.83 | TDP1 (0.48) | TDP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL505591 | 0.83 | PDGFRB (0.48) | TDP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL11066620 | 0.83 | ALDH1A1 (0.67) | TDP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL221958 | 0.83 | ALDH1A1 (0.46) | TDP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1549092 | 0.82 | ABL1 (0.48) | TDP1ABL1MEN1KMT2AMAPT | |
| SCHEMBL505294 | 0.82 | KDM4E (0.57) | TDP1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL1462927 | 0.82 | TDP1 (0.47) | TDP1ABL1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025023769-A1 | NOVEL SYNTHESIS METHOD OF 18F-RUCAPARIB | 고려대학교 산학협력단 | 2025-01-30 | — | — | WO | disclosed |
| CN-107922430-B | 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-09-04 | — | — | CN | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014092104-A1 | OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL USE OF SAME | 大日本住友製薬株式会社 (JP) | 2014-06-19 | — | — | WO | disclosed |
| EP-2561759-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth | Bayer Cropscience AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20110218103-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles | BAYER CROPSCIENCE AG (DE) | 2011-09-08 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-4769384-A | ANTIULCER AGENTS | NIPPON SHINYAKU CO. LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | TDP1 316/4885ABL1 3163/4885MEN1 1133/4885 |
| US-20110218103-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles | BOLA2; BOLA2B, ARFIP2, PFAS | TDP1 4069/4885ABL1 166/4885MEN1 4324/4885 |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | TDP1 4318/4885ABL1 92/4885MEN1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.